Cefazolin and Adcirca drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Cefazolin (cefazolin sodium) and Adcirca (tadalafil). Common drug interactions include bronchitis among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Cefazolin and Adcirca. It is created by eHealthMe based on reports of 100 people who take the same drugs from the FDA, and is updated regularly.

What is Cefazolin?

Cefazolin has active ingredients of cefazolin sodium. It is often used in infection. eHealthMe is studying from 15,157 Cefazolin users. Check the latest studies of Cefazolin.

What is Adcirca?

Adcirca has active ingredients of tadalafil. It is often used in pulmonary hypertension. eHealthMe is studying from 54,957 Adcirca users. Check the latest studies of Adcirca.



On Aug, 01, 2026

100 people who take Cefazolin and Adcirca together, and have interactions are studied.

Cefazolin and Adcirca drug interactions.

What are the common drug interactions of Cefazolin and Adcirca, by gender? *:

female:

  1. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  2. Dyspnoea (difficult or laboured respiration)
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Chest discomfort
  5. Pain
  6. Weight increased
  7. Atelectasis (partial or complete collapse of the lung)
  8. Cardioversion
  9. Dizziness
  10. Procedural pain

male:

  1. Pneumonia
  2. Hypoxia (low oxygen in tissues)
  3. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  4. Rash
  5. Thrombocytopenia (decrease of platelets in blood)
  6. Diarrhoea
  7. Sepsis (a severe blood infection that can lead to organ failure and death)
  8. Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin)
  9. Adenoidal hypertrophy (enlarged adenoids)
  10. Biliary colic

What are the common drug interactions of Cefazolin and Adcirca, by age (0-1 to 60+)? *:

0-1:

  1. Adenoidal hypertrophy (enlarged adenoids)
  2. Erythromelalgia (episodes of pain, redness, and swelling in various parts of the body)
  3. Femur fracture
  4. Pneumonia
  5. Hypoxia (low oxygen in tissues)
  6. Anaemia (lack of blood)
  7. Catheter site erythema (redness of skin at catheter site)
  8. Chylothorax (collection of lymph fluid around the lung)
  9. Diarrhoea
  10. Erythema (redness of the skin)

2-9:

  1. Hypoxia (low oxygen in tissues)
  2. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  3. Device related infection
  4. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  5. Pneumonia

10-19:

  1. Diarrhoea
  2. Headache (pain in head)
  3. Nasopharyngitis (inflammation of the nasopharynx)
  4. Platelet count decreased
  5. Procedural pain
  6. Procedural vomiting
  7. Urticaria (rash of round, red welts on the skin that itch intensely)
  8. Vomiting
  9. Device related infection
  10. Catheter site infection (infection at the site of insertion)

20-29:

  1. Headache (pain in head)
  2. Platelet count decreased
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Diarrhoea
  6. Pulmonary alveolar haemorrhage (acute bleeding)
  7. Liver disorder (liver diseases)
  8. Oxygen saturation decreased
  9. Pulmonary oedema (fluid accumulation in the lungs)
  10. Atelectasis (partial or complete collapse of the lung)

30-39:

  1. Anaemia (lack of blood)
  2. Device related infection
  3. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  4. Cardioversion
  5. Syncope (loss of consciousness with an inability to maintain postural tone)
  6. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  8. Pneumonia
  9. Rash
  10. Right ventricular failure (right half of the heart fails to work)

40-49:

  1. Nausea (feeling of having an urge to vomit)
  2. Device dislocation
  3. Device related infection
  4. Pain
  5. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  6. Dermatitis contact (skin reaction (dermatitis) resulting from exposure to allergens)
  7. Haemorrhagic diathesis (bleeding tendency)
  8. Prurigo (chronic skin disease causing severe itching)
  9. Pyrexia (fever)
  10. Stitch abscess (pus in stitches)

50-59:

  1. Oxygen saturation decreased
  2. Secretion discharge
  3. Vomiting
  4. Brain neoplasm (tumour of brain)
  5. Dizziness
  6. Malaise (a feeling of general discomfort or uneasiness)
  7. Orthostatic hypotension (a medical condition consisting of a sudden decrease in blood pressure when a person stands up)
  8. Seizure (abnormal excessive or synchronous neuronal activity in the brain)
  9. Gait disturbance
  10. Immobile (not moving)

60+:

  1. Right ventricular failure (right half of the heart fails to work)
  2. Renal impairment (severely reduced kidney function)
  3. Brain natriuretic peptide increased
  4. Chronic gastritis (long lasting infection of stomach lining)
  5. Craniotomy
  6. Depression
  7. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  8. Headache (pain in head)
  9. Hepatic enzyme increased
  10. Hypokalaemia (low potassium)

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 94 people, 94.00%
  2. Hypokalemia (low potassium): 31 people, 31.00%
  3. Right Ventricular Failure (right half of the heart fails to work): 25 people, 25.00%
  4. Cardiac Failure: 19 people, 19.00%
  5. Device Related Infection: 17 people, 17.00%
  6. Fever: 15 people, 15.00%
  7. Diarrhea: 14 people, 14.00%
  8. Sedation: 13 people, 13.00%
  9. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 10 people, 10.00%
  10. Anaemia (lack of blood): 9 people, 9.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cefazolin and Adcirca?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Cefazolin and Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cefazolin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Adcirca:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cefazolin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Adcirca and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cefazolin sodium and tadalafil (the active ingredients of Cefazolin and Adcirca, respectively), and Cefazolin and Adcirca (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: